Login to Your Account



Two NHL Vaccines Left Standing

MyVax Trial Failure Leaves Firm Hopeful, Others Not So

By Trista Morrison


Wednesday, December 26, 2007
Genitope Corp. revealed that cancer vaccine MyVax missed its primary endpoint in a pivotal Phase III trial, failing to improve progression-free survival compared to control in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription